{"id":63152,"date":"2026-04-14T23:05:44","date_gmt":"2026-04-14T15:05:44","guid":{"rendered":"https:\/\/flcube.com\/?p=63152"},"modified":"2026-04-14T23:05:45","modified_gmt":"2026-04-14T15:05:45","slug":"daiichi-sankyo-merck-ifinatamab-deruxtecan-granted-fda-priority-review-for-extensive-stage-sclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63152","title":{"rendered":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC"},"content":{"rendered":"\n<p><strong>Daiichi Sankyo<\/strong> (TYO: 4568) and <strong>Merck &amp; Co., Inc.<\/strong> (MSD; <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) announced that the <strong>Biologics License Application (BLA)<\/strong> for <strong>ifinatamab deruxtecan (I-DXd)<\/strong> has been <strong>accepted and granted Priority Review<\/strong> by the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>adult patients with extensive-stage small cell lung cancer (ES-SCLC)<\/strong> who have experienced disease progression on or after platinum-based chemotherapy. The <strong>PDUFA action date<\/strong> is set for <strong>October 10, 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Daiichi Sankyo (TYO: 4568) and Merck &amp; Co. (NYSE: MRK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Ifinatamab deruxtecan (I-DXd)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Biologics License Application (BLA)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Accepted with Priority Review<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Extensive-stage small cell lung cancer (ES-SCLC) post-platinum chemotherapy<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>October 10, 2026<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Potential first-in-class B7-H3 directed DXd antibody drug conjugate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> Specifically engineered B7-H3 directed DXd antibody drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Discovery Origin:<\/strong> Discovered by Daiichi Sankyo, jointly developed with MSD<\/li>\n\n\n\n<li><strong>Target:<\/strong> B7-H3 (CD276) \u2013 immune checkpoint protein overexpressed in multiple solid tumors including SCLC<\/li>\n\n\n\n<li><strong>Payload:<\/strong> DXd (deruxtecan) \u2013 topoisomerase I inhibitor with high potency and bystander effect<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> Would be the first B7-H3 directed ADC approved for any indication if successful<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Addresses critical gap in ES-SCLC treatment where options are limited after platinum failure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-base\">Clinical Evidence Base<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-primary-supporting-trial-ideate-lung01-phase-2\">Primary Supporting Trial: IDeate-Lung01 Phase 2<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> ES-SCLC patients with disease progression after platinum-based chemotherapy<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Objective response rate (ORR) and duration of response (DoR)<\/li>\n\n\n\n<li><strong>Key Results:<\/strong> Demonstrated clinically meaningful anti-tumor activity with manageable safety profile<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-supporting-data-ideate-pantumor01-phase-1-2\">Supporting Data: IDeate-PanTumor01 Phase 1\/2<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design:<\/strong> Multi-tumor basket trial evaluating I-DXd across various B7-H3 expressing cancers<\/li>\n\n\n\n<li><strong>Contribution:<\/strong> Provided additional safety data and confirmed target engagement across tumor types<\/li>\n\n\n\n<li><strong>SCLC Cohort:<\/strong> Reinforced efficacy signals observed in the dedicated lung cancer trial<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ES-SCLC Burden:<\/strong> Approximately 30,000 new cases annually in the US with poor prognosis post-platinum<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Limited effective options after first-line therapy failure create premium positioning opportunity<\/li>\n\n\n\n<li><strong>B7-H3 Target Validation:<\/strong> Success would validate B7-H3 as a therapeutically relevant target across oncology<\/li>\n\n\n\n<li><strong>ADC Leadership:<\/strong> Strengthens Daiichi Sankyo&#8217;s position as ADC technology leader alongside Enhertu franchise<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-strategy\">Commercial Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Power:<\/strong> First-in-class status and unmet need support premium pricing<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Priority Review designation may accelerate payer coverage decisions<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> US approval would facilitate regulatory submissions in EU, Japan, and other major markets<\/li>\n\n\n\n<li><strong>Pipeline Catalyst:<\/strong> Success could accelerate development in other B7-H3 expressing tumors including prostate, ovarian, and pediatric cancers<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standard:<\/strong> Limited options include topotecan, lurbinectedin, and clinical trials<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Novel target (B7-H3) avoids competition with established pathways<\/li>\n\n\n\n<li><strong>ADC Competition:<\/strong> Distinct from other SCLC ADCs targeting different antigens like DLL3<\/li>\n\n\n\n<li><strong>Bystander Effect:<\/strong> DXd payload may provide advantage in heterogeneous tumor environments<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>The companies will prepare for potential commercial launch in Q4 2026, pending FDA approval. Additional regulatory submissions in other geographies are expected to follow the US decision.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approval, commercial expectations, and development plans for ifinatamab deruxtecan. Actual results may differ due to risks including FDA review outcomes, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo (TYO: 4568) and Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,194,120,2675,176,903,80,978],"class_list":["post-63152","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-daiichi-sankyo","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-priority-reviews","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo (TYO: 4568) and Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63152\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo (TYO: 4568) and Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63152\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T15:05:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T15:05:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC\",\"datePublished\":\"2026-04-14T15:05:44+00:00\",\"dateModified\":\"2026-04-14T15:05:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152\"},\"wordCount\":522,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Daiichi Sankyo\",\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Priority reviews\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63152#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63152\",\"name\":\"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T15:05:44+00:00\",\"dateModified\":\"2026-04-14T15:05:45+00:00\",\"description\":\"Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63152\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63152#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63152","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC","og_description":"Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.","og_url":"https:\/\/flcube.com\/?p=63152","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T15:05:44+00:00","article_modified_time":"2026-04-14T15:05:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63152#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63152"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC","datePublished":"2026-04-14T15:05:44+00:00","dateModified":"2026-04-14T15:05:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63152"},"wordCount":522,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Daiichi Sankyo","Merck","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Priority reviews","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63152#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63152","url":"https:\/\/flcube.com\/?p=63152","name":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T15:05:44+00:00","dateModified":"2026-04-14T15:05:45+00:00","description":"Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression on or after platinum-based chemotherapy. The PDUFA action date is set for October 10, 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63152#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63152"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63152#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63152"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63152\/revisions"}],"predecessor-version":[{"id":63154,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63152\/revisions\/63154"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}